

Curriculum Vitae

Personal data:

Name: Abdo Mahli
 Nationality: German/ Syrian
 Date of birth: 30.07.1983
 Address: Amman, Jordan
 Email: abdoliver@gmail.com
 Telephone: Germany: +491776192137
 Jordan: +962 799 148 730



Brief Synopsis	<p>-PhD in Pharmacy with profound expertise in pharmacology, as well as medical biochemistry, pharmaceutical biotechnology, PK/PD studies, and up to Phase III clinical trials conducted under GCP standards.</p> <p>-Outstanding expertise in the development of novel biologics and biosimilars, pioneering research in experimental oncology and hepatology, and the development and validation of sophisticated bioanalytical methods, including PK, ADA, and Nab assays.</p> <p>-The inaugural Arab scientist to be awarded the best scientific publication prize in Germany for the year 2018, (impact factor 25; <i>Mahli et al. Gut</i>; 2018).</p> <p>-Editor in Chief for “<i>BioTech Arab World</i>” journal exclusively focused on biologics and biosimilars. To date, successfully published two issues.</p> <p>-Member of the scientific committee of the “Arab Union of the Manufacturers of Pharmaceuticals and Medical Appliances -AUPAM-”.</p>
Professional Experience	<p>Sep.2023-Current: Assistant Professor at the faculty of pharmaceutical and chemical engineering (PCE), German Jordanian University (GJU), Amman, Jordan.</p> <p>Mar.2022-Aug.2023: Assistant Professor at the Faculty of Pharmacy, Petra University, Amman, Jordan.</p> <p>Mar.2022-Current: Freelance Consultant for BioAgilytix Europa GmbH, Hamburg, Germany.</p> <p>Feb.2020-Feb.2022: Principal Investigator at BioAgilytix Europa GmbH, Hamburg, Germany. https://www.bioagilytix.com. Supervising more than 30 projects for Novartis, Sanofi, UCB, Pfizer among others.</p> <p>Oct.2019-Jan.2020: Paternity leave.</p> <p>Sep.2016-Sep.2019: Assistant Professor in clinical biochemistry & molecular pharmacology at the institute of Biochemistry, College of Medicine, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany (196th World University Rankings 2023).</p> <p>Jan.2014-Aug.2016: Postdoc researcher at the department of Internal Medicine, University Hospital Regensburg, Regensburg, Germany.</p> <p>Sep.2009-Dec.2013: Scientific Researcher at the department of Internal Medicine, University Hospital Regensburg, Regensburg, Germany.</p> <p>Jul.2007-Jun.2008: Associate Head of R&D department at Asia for pharmaceutical industry, Aleppo, Syria.</p> <p>Jan.2005-Jun.2007: Medical science liaison at Ibn-Alnafis Pharma, Aleppo, Syria.</p>
Education	<p>Dec.2013: PhD degree in Pharmacy. <u>Doctoral thesis:</u>” <i>Novel in vitro model for combined effects of alcohol and free fatty acids on hepatocellular lipid accumulation and inflammation</i>” (Note: 1.0, magna cum laude).</p> <p>Sep.2009-Nov.2013: PhD student at the department of Internal Medicine I at the University Hospital Regensburg.</p> <p>Oct.2008-Aug.2009: Certificate equivalence at the Faculty of Pharmacy, University of Regensburg, Regensburg, Germany.</p> <p>Sep.2002-Jun.2007: bachelor’s degree in pharmacy and Pharmaceutical Chemistry (rate: very good), University of Aleppo, Aleppo, Syria.</p>
Main Industrial expertise,	<ul style="list-style-type: none"> - Pharmacology & Experimental Hepatology and Oncology - Medical Biochemistry - Pharmaceutical Biotechnology - Development of novel (Immune) Biotherapeutics and Biosimilars

Curriculum Vitae

teaching and Research areas	<ul style="list-style-type: none"> - Development and Validation of Cell-based and CLB assays (PK, PD, Biomarkers, ADA and Nab assays) - Phytotherapy
Awarded Funding	<p>1- MediPlant-Project granted by DAAD (Ta'ziz Networking 2023–2025): 125 K/year over three years (375 K Euro in total) in collaboration with Marburg University in Germany.</p> <p>2- Internal Petra Funding: 10 K/year.</p>
Scientific Activities	<p>Original Publications</p> <ol style="list-style-type: none"> 1- Sarfaraz K. Niazi1 & Abdo Mahli, Becoming Self-sufficient in Biological Drugs Supply, <i>BioTech Arab World Journal</i>, Vol2. 2023. https://lnkd.in/dnwVZP4A 2- Mahli A, Thasler WE, Biendel M and Hellerbrand C. Hop-derived humulinones reveal protective effects in <i>in vitro</i> models of hepatic steatosis, inflammation and fibrosis. <i>Planta Med.</i> 2023 (doi: 10.1055/a-2103-3230. Online ahead of print). 3- Sayed Issa R, Mushtaq G, Unnisa A and Mahli A. A case of concomitant leukemoid reaction and mucormycosis in a patient with severe COVID-19 infection, <i>Turkish Journal of Biochemistry.</i> 2023. https://doi.org/10.1515/tjb-2023-0016 4- Seitz T, Hackl C, Dietrich P, Mahli A, Thasler RM, Thasler WE, Lang SA, Bosserhoff AK, Hellerbrand C. Xanthohumol, a prenylated chalcone derived from hops, inhibits growth and metastasis of melanoma cells. <i>Cancers</i> 2021, 13(3), 511. 5- Mahli A, Seitz T, Beckröge T, Freese K, Thasler WE, Benkert M, Dietrich P, Weiskirchen R, Bosserhoff A, Hellerbrand C. Bone Morphogenetic Protein-8B Expression is Induced in Steatotic Hepatocytes and Promotes Hepatic Steatosis and Inflammation In Vitro. <i>Cells.</i> 2019 May 15;8(5). pii: E457. doi: 10.3390/cells8050457. 6- Mahli A, Seitz T, Freese K, Frank J, Weiskirchen R, Abdel-Tawab M, Behnam D, Hellerbrand C. Therapeutic Application of Micellar Solubilized Xanthohumol in a Western-Type Diet-Induced Mouse Model of Obesity, Diabetes and Non-Alcoholic Fatty Liver Disease. <i>Cells.</i> 2019 Apr 17;8(4). pii: E359. doi: 10.3390/cells8040359. 7- Mahli A, Thasler WE, and Hellerbrand C. Establishment of a p-nitrophenol oxidation-based assay for the analysis of CYP2E1 activity in intact hepatocytes in vitro. <i>Toxicol Mech Methods.</i> 2019 Mar;29(3):219-223. doi: 10.1080/15376516.2018.1539800. Epub 2018 Dec 21. 8- Mahli A, Koch A, Freese K, Thasler WE, Berghem I, Schönberger C, Bosserhoff A, Hellerbrand C. Iso-Alpha Acids (IAA) from hops (<i>Humulus lupulus</i>) inhibit hepatic steatosis, inflammation and fibrosis. <i>Lab Invest.</i> 2018 Dec;98(12):1614-1626. doi: 10.1038/s41374-018-0112-x. Epub 2018 Aug 8. 9- Mahli A, Saugspier M, Koch A, Sommer J, Dietrich P, Lee S, Thasler R, Schulze-Luehrmann J, Luehrmann A, Thasler WE, Müller M, Bosserhoff A, Hellerbrand C. ERK activation and autophagy impairment are central mediators of irinotecan-induced steatohepatitis. <i>Gut.</i> 2018 Apr;67(4):746-756. doi: 10.1136/gutjnl-2016-312485. Epub 2017 Jan 4. 10- Hammad H, Othman A, Mahli A, ..., Dooley S. Confounding influence of tamoxifen in mouse models of Cre recombinase-induced gene activity or modulation. (<i>Arch Toxicol.</i> 2018 Jul 4. doi: 10.1007/s00204-018-2254-4. [Epub ahead of print]). 11- Dietrich P, Freese K, Mahli A, Thasler WE, Hellerbrand C, Bosserhoff AK. Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic „dual-hit“ option. <i>Oncotarget.</i> 2018; 9:3605-3618. 12- Koletzko L, Mahli A and Hellerbrand C. Development of an in vitro model to study hepatitis C virus effects on hepatocellular lipotoxicity and lipid metabolism. <i>Pathology - Pathol Res Pract.</i> 2018 Oct;214(10):1700-1706. doi: 10.1016/j.prp.2018.08.013. Epub 2018 Aug 19. 13- Mahli A*, Sommer J*, Freese K, Schiergens TS, Kuecukoktay FS, Teufel A, Thasler WE, Müller M, Bosserhoff AK, Hellerbrand C. (2016), Analysis of molecular mechanisms of 5-fluorouracil-induced steatosis and inflammation in vitro and in mice. <i>Oncotarget.</i> 2017 Feb 21;8(8):13059-13072. doi: 10.18632/oncotarget.14371. *: equal contribution. 14- Mahli A, Hellerbrand C. Alcohol and Obesity: A Dangerous Association for Fatty Liver Disease. <i>Dig Dis.</i> 2016;34 Suppl 1:32-9. doi: 10.1159/000447279. 15- Mahli A, Thasler WE, Patsenker E, Müller S, Stickel F, Müller M, Seitz HK, Cederbaum AI, Hellerbrand C. Identification of cytochrome CYP2E1 as critical mediator of synergistic effects of alcohol and cellular lipid accumulation in hepatocytes in vitro. <i>Oncotarget.</i> 2015 Dec 8;6(39):41464-78. doi: 10.18632/oncotarget.6203.

Curriculum Vitae

	<p>16- Mahli A, Koch A, Czech B, Peterburs P, Lechner A, Haunschild J, Müller M and Hellerbrand C. Hepatoprotective effect of oral application of a silymarin extract in carbon tetrachloride-induced hepatotoxicity in rats. <i>Clinical Phytoscience</i>. 2015-1:5 DOI: 10.1186/s40816-015-0006-z.</p> <p>17- Koch A, Lang SA, Wild PJ, Gantner S, Mahli A, Spanier G, Berneburg M, Müller M, Bosserhoff AK, Hellerbrand C. Glucose transporter isoform 1 expression enhances metastasis of malignant melanoma cells. <i>Oncotarget</i>. 2015 Oct 20;6(32):32748-60. doi: 10.18632/oncotarget.4977.</p> <p>18- Mahli A*, Weiskirchen R*, Weiskirchen S, Hellerbrand C. The hop constituent xanthohumol exhibits hepatoprotective effects and inhibits the activation of hepatic stellate cells at different levels. <i>Front Physiol</i>. 2015 May 6;6:140.doi:10.3389/fphys.2015.00140. *: equal contribution.</p> <p>Oral presentations</p> <p>1- [GASL.2018]: Presentation for GASL PRIZE (Yael Foundation Ceremony).</p> <p>2- [GASL.2014]: Protective effects of Iso-Alpha Acids (IAA) on hepatic steatosis, inflammation, and fibrosis.</p> <p>3- [DGVS.2013]: Cytochrome CYP2E1 is critical for joint effects of alcohol and lipids on hepatocellular steatosis and inflammation.</p>
Awards	<p>1- GASL Prize of the Yael foundation (Best scientific publication in all Germany for the year 2018; Hamburg, Germany; 2018) https://yael-stiftung.de/en/activities/gasl-award-of-the-yael-foundation/laureate-2018/</p> <p>2- EASL Young Investigator Bursary (Full Bursary, one of the best 200 abstracts worldwide), (European Association for the Study of the Liver; Vienna, Austria; 2015)</p> <p>3- EASL Young Investigator Bursary (Registration Bursary, European Association for the Study of the Liver; Barcelona, Spain; 2012)</p> <p>4- Travel Awards from Falk workshop for the Years (2012, 2013, 2014, 2016, 2017 and 2018)</p>
Technical Courses	<p>1- Project Management Workshop: to support the funding of Ta'ziz Networking 2023–2025 program.</p> <p>2- Customer Service Excellence Workshop (https://www.creoinc.net); Advanced training course for optimal customer service & Business/products Strategy & Operations.</p> <p>3- Professionalization in Teaching: training courses for instructors on international teaching standards completed by obtaining the “<i>certificate for Teaching in Higher Education of the Bavarian Universities</i>”.</p> <p>4- Advanced training courses for “<i>Project Manager and Biosafety Officer (BBS)</i>” gained at the University Hospital Regensburg.</p> <p>5- Advanced training courses for “<i>Animal experimentation and animal welfare (according to the FELASA-B guidelines)</i>” at the University Hospital Regensburg (Oct.2014 plus regular training (two hours concept) for the years 2015 up to 2019).</p> <p>6- GASL-Hands-On Workshop (<i>advanced training course for hepatic cells isolation Techniques</i>), Düsseldorf, Germany.</p> <p>7- Zeiss Microscopy Techniques (basic and advanced) at Carl Zeiss Microscopy GmbH, Munich.</p>
Patents	<p>Pharmaceutical composition for inhibiting human CYP450 enzymes, preferably the CYP2E1 enzyme. Patent number: EP 3207924 A1 Inventors: Dr. Abdo Mahli and Prof. Dr. Claus Hellerbrand</p>
Languages	<p>1- Arabic: native speaker 2- English: Fluent in spoken and written 3- German: Fluent in spoken and written 4- Turkish: Elementary</p>
Related Websites	<p>https://www.linkedin.com/in/abdo-mahli-6093a411b/ https://orcid.org/0000-0002-8333-7551</p>